Recent

% | $
Quotes you view appear here for quick access.

OCATA THERAPEUTICS, INC. Message Board

dynammo_humm 3 posts  |  Last Activity: Jun 23, 2015 10:59 PM Member since: Mar 29, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • dynammo_humm by dynammo_humm Apr 30, 2015 12:36 PM Flag

    12:30 PM ET 04/30/2015

    MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Ocata Therapeutics, Inc. , a leader in the field of Regenerative Ophthalmology™, announced that a study has been published that includes top-line, positive results in Asian patients who were treated with Ocata’s proprietary RPE cells, manufactured using its DeltaCell™ Technology.

    These new data support previously reported positive long-term safety and signs of visual improvement, as presented in The Lancet of October 15th, 2014. The Korean study published online in Stem Cell Reports features twelve months of post-transplant follow-up data from four Asian patients; two with Stargardt’s macular degeneration (SMD) and two with dry age-related macular degeneration (AMD).

    “The results of this study conducted by CHA Biotech in Asian patients support the findings published in The Lancet in October 2014 and further underscores our leadership in regenerative ophthalmology,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “The safe treatment of a total of forty two patients across multiple studies with this novel therapeutic approach in geographically distinct patient populations is encouraging. We look forward to the planned initiation of our comprehensive Phase 2 safety study in dry AMD and a pivotal study in SMD, two disabling diseases where there is no cure available today.”

    In this study there was no evidence of adverse proliferation, tumorigenic behavior, ectopic tissue formation, or other serious safety issues related to the transplanted cells. Although designed as a safety study, visual acuity improved 9–19 letters in three patients and remained stable (+1 letter) in one patient. Vision was measured using the widely accepted standard for visual acuity testing, the Early Treatment Diabetic Retinopathy Study visual acuity exam.

    Robert Lanza, M.D., Chief Scientific Officer of Ocata Therapeutics ( OCAT ) and co-senior author of the paper, commented, “These results support the potential

  • dynammo_humm by dynammo_humm May 21, 2015 8:12 AM Flag

    I was playing solitaire on my I-Pad last night and a full screen ad for Empire and Allies came up. It had a good looking picture and a caption stating 'Over 2,00,000 Players".

    Nice way of targeting mobile gamers without spending too much money.

  • dynammo_humm dynammo_humm Jun 23, 2015 10:59 PM Flag

    Netflix was a $5.00 stock 10 years ago. Just broke $700.00. Good things take time which is why I have this in a Roth IRA. When I retire that will be some nice tax free income...

ACTC
0.00(0.00%)